Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: lawrence lerner who wrote (1084)	7/31/1999 1:39:00 PM
From: D. Chapman	Read Replies (3) \| Respond to of 1972

To all who disagree w/ my OPINIONS, let's just wait it out a few days and see who's right... I will not post any negative comments to anyone... if you all are confident about the stock, then, by all means, buy it... But I personally see no reason to encourage buying the stock, given that there is absolutely no new info. nor any evidence to suggest a buyout... Oh and on another note, wrt vaccine aspect, I think there is something here... Any injection of foreign dna in a host will stimulate a response such that any second exposure to agent will trigger a more magnified, memory-oriented secondary immune response... but I still do not think this company will ever produce a viable cancer treatment... And Mr.(or Ms.) Boganoff, wrt percentages, there are other companies in current FDA trials producing agents which alleviate tumor in far greater percentages than VICL's product... WRT other companies which appreciate due to "1% results," Cor Therapeutics produces agents which treat unstable (i.e., Prinzmetal's) angina, for which there is currently NO truly reliable treatment option... That is why even single digit percentage improvements give strength to this company, while will not do so for other companies, especially those who wish to treat cancer...